Healthcare Industry News: Avalon Pharmaceuticals
News Release - June 16, 2008
Lentigen Appoints Jim Meade as Vice President of Corporate DevelopmentBALTIMORE, June 16 (HSMN NewsFeed) -- Lentigen Corporation today announced the appointment of Jim Meade, Ph.D., CLP, as vice president of corporate development. In addition to contributing to the strategic direction of the company, Dr. Meade will be responsible for managing the development of Lentigen's partnerships, stakeholder relations, product and intellectual property portfolios, contract negotiations, and other key aspects of corporate development.
Tim Ravenscroft, CEO of Lentigen, commented, "Jim's extensive background in strategic development, opportunity evaluation, and negotiation will be an important asset to Lentigen as we continue to advance our business opportunities and collaborative relationships in biotherapeutics, vaccines and protein production."
Dr. Meade previously worked at Avalon Pharmaceuticals, where he served as vice president of business development. With more than 30 years' experience in the pharmaceutical and biotechnology industries, he has also held senior-level positions at Pharmacia, Bayer and Chiron. He holds a Ph.D. in molecular biology from the University of Texas, and is a Certified Licensing Professional and an active member of the Licensing Executives Society.
About Lentigen Corporation
Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit www.lentigen.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.